Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators

Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ Healthcare (Korea) for the treatment of gastroesophageal reflux disease and helicobacter pylori infections. Tegoprazan is mainly metabolized by cytochrome P450 (CYP) 3A4. Considering the therapeutic indications, tegopra...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngo, Lien Thi, Lee, Jaeyeon, Yun, Hwi-yeol, Chae, Jung-woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862396/
https://www.ncbi.nlm.nih.gov/pubmed/36678810
http://dx.doi.org/10.3390/pharmaceutics15010182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862396/
https://www.ncbi.nlm.nih.gov/pubmed/36678810
http://dx.doi.org/10.3390/pharmaceutics15010182

Ejemplares similares